How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in Exact Sciences (
EXAS Quick Quote EXAS - Free Report) ten years ago? It may not have been easy to hold on to EXAS for all that time, but if you did, how much would your investment be worth today? Exact Sciences' Business In-Depth
With that in mind, let's take a look at Exact Sciences' main business drivers.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics.
On Nov 8, 2019, Exact Sciences completed the acquisition of Genomic Health for a value of approximately $2.8 billion. Prior to merger, Genomic Health was a prominent provider of genomic-based diagnostic tests in the field of cancer care. The company used to offer its line of products under the brand name Oncotype DX.
Following the consolidation, Exact Sciences currently has two of the strongest brands in cancer diagnostics, Cologuard and Oncotype DX.
Cologuard Test: This is a non-invasive stool-based DNA (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Oncotype DX: Genomic Health’s first product, the 21-gene Oncotype DX breast cancer test launched in Jan 2004, is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.
In Jan 2010, Genomic launched its Oncotype DX colon cancer test to predict individual recurrence risk in stage II colon cancer patients post-surgery although the test is yet to make any significant contribution to the top line. In May 2013, Genomic Health commercialized Oncotype DX prostate cancer test.
Exact Sciences acquired Paradigm Diagnostics and Viomics in March 2020, Base Genomics Limited in October 2020 and Thrive Earlier Detection Corporation in January 2021.
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Exact Sciences ten years ago, you're likely feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in May 2013 would be worth $7,218.86, or a 621.89% gain, as of May 31, 2023. Investors should keep in mind that this return excludes dividends but includes price appreciation.
The S&P 500 rose 154.20% and the price of gold increased 35.93% over the same time frame in comparison.
Analysts are forecasting more upside for EXAS too.
Exact Sciences exited the first quarter of 2023 with better-than-expected results. The quarterly loss narrowed significantly from the year-ago period’s levels. Robust revenues from the Screening and Precision Oncology segments contributed to the first-quarter top line. During the quarter, 10,000 new healthcare professionals ordered Cologuard, bringing the total to over 312,000. The growing uptake of the company’s Oncotype DX Breast and therapy selection products which helps in the diagnosis of early-stage breast cancer looks encouraging. The raised 2023 guidance is a major upside. Year-to-date, Exact Sciences has outperformed its industry. However, the decline in COVID-19 sales hampered top-line growth. The company incurred an operating loss, raising apprehension.
The stock is up 28.61% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 7 higher, for fiscal 2023. The consensus estimate has moved up as well.